Virtu KCG Holdings’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Virtu KCG Holdings’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$211K	Sell	4,630 -4,705	-50%	-$203K	0.01%	2106
2017 Q1	$395K	Buy	9,335 +3,561	+62%	+$149K	0.01%	1625
2016 Q4	$224K	Sell	5,774 -8,353	-59%	-$337K	0.01%	2456
2016 Q3	$593K	Sell	14,127 -10,217	-42%	-$420K	0.01%	1208
2016 Q2	$900K	Sell	24,344 -6,810	-22%	-$267K	0.02%	841
2016 Q1	$1.19M	Buy	31,154 +12,265	+65%	+$477K	0.03%	497
2015 Q4	$954K	Sell	18,889 -14,132	-43%	-$698K	0.02%	906
2015 Q3	$1.51M	Buy	33,021 +28,462	+624%	+$1.59M	0.02%	589
2015 Q2	$266K	Buy	4,559 +793	+21%	+$45.3K	﹤0.01%	2229
2015 Q1	$208K	Buy	+3,766	New	+$204K	﹤0.01%	2356
2014 Q3	–	Sell	-36,178	Closed	-$1.58M	–	3934
2014 Q2	$1.58M	Sell	36,178 -26,913	-43%	-$1.09M	0.02%	719
2014 Q1	$2.63M	Buy	+63,091	New	+$2.7M	0.03%	533
2013 Q4	–	Sell	-19,286	Closed	-$676K	–	4124
2013 Q3	$676K	Buy	+19,286	New	+$639K	0.01%	1636

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Virtu KCG Holdings's PBE Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 50% in Q2 2017, selling an estimated $203K and leaving 4,630 shares worth $211K. The position accounts for 0.01% of the portfolio, ranked #2106.

Virtu KCG Holdings first reported a position in PBE in Q3 2013 and has held it in 13 quarters since. The position peaked at $2.63M in Q1 2014. 64 funds tracked by Wall St. Rank hold PBE as of Q2 2017.

Virtu KCG Holdings held 4,630 shares of Invesco Biotechnology & Genome ETF worth $211K as of Q2 2017.
Virtu KCG Holdings sold 4,705 Invesco Biotechnology & Genome ETF shares in Q2 2017, an estimated $203K.
Invesco Biotechnology & Genome ETF made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2106 holding.
Virtu KCG Holdings first reported a position in Invesco Biotechnology & Genome ETF in Q3 2013 and has held it in 13 quarters since.
Virtu KCG Holdings's Invesco Biotechnology & Genome ETF position peaked at $2.63M in Q1 2014.
64 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.